论文部分内容阅读
Rosenberg博士在第七届化疗基金会专题讨论会上谈到选择性免疫治疗。选择性免疫治疗与目前常用的绝大多数免疫疗法充全不同,作者是将具有抗瘤活性的淋巴细胞转移给肿瘤宿主,而后者是用非特异的方式刺激免疫系统。在选择性免疫治疗时,活性免疫因子是具有免疫活性的免疫细胞。产生能够自我识别和杀伤肿瘤的免疫细胞的主要障碍是在大量的细胞中鉴别具有足够抗瘤效应的细胞。淋巴活性样杀伤细胞(LAK-Cell)是在培养中能调理抗瘤效应的细胞,在体外实验中,在白细胞介素-2(IL-2)中孵3～4小时即可获得杀肿瘤细胞和异常细胞的能力,LAK细胞的前体是无活性的非
Dr. Rosenberg talked about selective immunotherapy at the 7th Chemotherapy Foundation Symposium. Selective immunotherapy is completely different from most immune therapies currently used. The authors transfer lymphocytes with anti-tumor activity to tumor hosts, which stimulate the immune system in a non-specific manner. In selective immunotherapy, active immune factors are immunologically active immune cells. The main obstacle to producing immune cells capable of self-recognition and killing of tumors is to identify cells with sufficient anti-tumor effects in a large number of cells. Lymphokinemic killer cells (LAK-Cell) are cells that can regulate anti-tumor effects in culture. In vitro experiments, kill tumor cells by incubation in interleukin-2 (IL-2) for 3 to 4 hours. And the ability of abnormal cells, LAK cell precursors are inactive